Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis
| العنوان: | Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis |
|---|---|
| المؤلفون: | Paiva, Bruno, Mateos, María Victoria, Sanchez-Abarca, Luis Ignacio, Puig, Noemi, Vidriales, María-Belén, López-Corral, Lucía, Corchete, Luis A, Hernandez, Miguel T, Bargay, Joan, de Arriba, Felipe, de la Rubia, Javier, Teruel, Ana-Isabel, Giraldo, Pilar, Rosiñol, Laura, Prosper, Felipe, Oriol, Albert, Hernández, José, Esteves, Graça, Lahuerta, Juan José, Bladé, Joan, Perez-Simon, Jose Antonio, San Miguel, Jesús F, Spanish Myeloma Group / Program Study and Treatment of Hematological Malignancies cooperative study groups |
| المساهمون: | Instituto de Salud Carlos III, Asociación Española Contra el Cáncer, European Research Council, Red Temática de Investigación Cooperativa en Cáncer (España) |
| المصدر: | Digital.CSIC. Repositorio Institucional del CSIC instname Blood r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe Dadun. Depósito Académico Digital de la Universidad de Navarra |
| بيانات النشر: | American Society of Hematology, 2016. |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_treatment, T-Lymphocytes, Immunology, Biochemistry, Dexamethasone, Immunophenotyping, Maintenance Chemotherapy, 03 medical and health sciences, 0302 clinical medicine, Immune system, Aldesleukin, Risk Factors, hemic and lymphatic diseases, Biomarkers, Tumor, Medicine, Humans, IL-2 receptor, Longitudinal Studies, Lenalidomide, Multiple myeloma, Aged, Cell Proliferation, Demography, Aged, 80 and over, business.industry, Cell Biology, Hematology, Immunotherapy, Induction Chemotherapy, Middle Aged, medicine.disease, Thalidomide, Immunosurveillance, Killer Cells, Natural, body regions, 030220 oncology & carcinogenesis, Female, Ciencias de la Salud::Hematología [Materias Investigacion], business, Multiple Myeloma, CD8, 030215 immunology, medicine.drug |
| الوصف: | On behalf of the Grupo Español de Mieloma/Programa de Estudio y Tratamiento de las Hemopatías Malignas cooperative study groups. There is significant interest in immunotherapy for the treatment of high-risk smoldering multiple myeloma (SMM), but no available data on the immune status of this particular disease stage. Such information is important to understand the interplay between immunosurveillance and disease transformation, but also to define whether patients with high-risk SMM might benefit from immunotherapy. Here, we have characterized T lymphocytes (including CD4, CD8, T-cell receptor γδ, and regulatory T cells), natural killer (NK) cells, and dendritic cells from 31 high-risk SMM patients included in the treatment arm of the QUIREDEX trial, and with longitudinal peripheral blood samples at baseline and after 3 and 9 cycles of lenalidomide plus low-dose dexamethasone (LenDex). High-risk SMM patients showed at baseline decreased expression of activation-(CD25/CD28/CD54), type 1 T helper-(CD195/interferon-γ/tumor necrosis factor-α/interleukin-2), and proliferation-related markers (CD119/CD120b) as compared with age-matched healthy individuals. However, LenDex was able to restore the normal expression levels for those markers and induced a marked shift in T-lymphocyte and NK-cell phenotype. Accordingly, high-risk SMM patients treated with LenDex showed higher numbers of functionally active T lymphocytes. Together, our results indicate that high-risk SMM patients have an impaired immune system that could be reactivated by the immunomodulatory effects of lenalidomide, even when combined with low-dose dexamethasone, and support the value of therapeutic immunomodulation to delay the progression to multiple myeloma. This study was supported by the Cooperative Research Thematic Network grants RD12/0036/0058 and RD12/0043/0012 of the Red de Cancer (Cancer Network of Excellence); Instituto de Salud Carlos III, Spain, Instituto de Salud Carlos III/Subdirección General de Investigación Sanitaria (FIS: PI060339; 06/1354; 02/0905; 01/0089/01-02; PS09/01897/01370; G03/136; and Sara Borrell: CD13/00340); Asociación Española Contra el Cáncer (GCB120981SAN), Spain; and a European Research Council 2015 Starting Grant (B.P.). |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 0006-4971 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a00af9d674b2dda137189561ec4bbb03Test https://hdl.handle.net/10171/52183Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....a00af9d674b2dda137189561ec4bbb03 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 00064971 |
|---|